Form 8-K Alkermes plc. For: Apr 19
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
ALKERMES PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
||
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
||
|
of incorporation) |
|
File Number) |
|
Identification No.) |
||
|
|
|
|
||||
|
|
|
|
||||
|
|
||||||
|
|
||||||
|
(Address of principal executive offices) |
||||||
Registrant's telephone number, including area code: +
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On April 19, 2022, Alkermes Pharma Ireland Limited, an indirect wholly-owned subsidiary of Alkermes plc (collectively with its subsidiaries, the “Company”) commenced arbitration proceedings in connection with Janssen Pharmaceutica N.V.’s (“Janssen”) partial termination in the United States of two license agreements with the Company (as successor in interest to Elan Pharmaceutical Research Corp., d/b/a Nanosystems and Elan Pharma International Limited). Under the license agreements, Janssen received access and rights to the Company’s small particle pharmaceutical compound technology, known as NanoCrystal® Technology, which enabled a number of products, such as INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® and CABENUVA®.
The duration and outcome of these arbitration proceedings are inherently uncertain. The Company intends to vigorously defend its intellectual property against any unauthorized use by Janssen. The Company disclaims any obligation to update or revise the information set forth in this Current Report on Form 8-K, whether as a result of new information, future events or otherwise, except as required by law.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ALKERMES PLC |
||
|
|
|
||
|
Date: April 19, 2022 |
By: |
|
/s/ David J. Gaffin |
|
|
|
|
David J. Gaffin |
|
|
|
|
Secretary |
3
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alkermes to Report First Quarter Financial Results on May 1, 2024
- Three Cargill Innovations Win the Prestigious 2024 Edison Awards™
- Shift4 to Release First Quarter Earnings Results on May 9, 2024
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
